帕金森病中缺氧条件:随机对照多重N-of-1试验中的1个
Jules M Janssen Daalen1,2, Marjan J Meinders1, Federica Giardina3
1Radboud University Medical Center; Donders Institute for Brain, Cognition and Behavior; Department of Neurology; Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands.
Nature communications
|September 26, 2025
概括
对帕金森病 (PD) 患者来说,缺氧条件是安全的和可行的,间歇性缺氧显示短期症状缓解. 进一步的研究将探索长期的益处和有效性.
科学领域:
- 神经学 神经学
- 运动生理学 运动生理学
- 临床试验 临床试验
背景情况:
- 临床前研究表明,低氧条件对帕金森病 (PD) 症状有好处,并提供神经保护.
- 调查低氧条件在PD中的安全性和有效性对于潜在的治疗应用至关重要.
- 目前对低氧条件对PD症状和生物标志物的影响的理解有限.
研究的目的:
- 评估PD患者的各种缺氧调节方案的安全性和可行性.
- 评估低氧条件对PD的短期症状影响.
- 探索下游效应和与PD中低氧条件相关的潜在生物标志物.
主要方法:
- 20名患有PD的个人 (Hoehn-Yahr 1.5-3) 参加了一项随机,双盲,安慰剂控制的N-of-1试验.
- 参与者接受了五次45分钟的低氧干预 (连续和间歇的FiO20.163和0.127) 和安慰剂干预,两次.
- 测量了安全性,可行性,症状评分 (参与者和评估者评分),以及探索性血清生物标志物 (EPO,BDNF,GFAP,NfL,PDGFRβ,皮质醇).
主要成果:
- 该研究满足了安全性和可行性的主要终点,低氧条件被很好地容忍.
- 95个不良事件发生,没有剂量依赖,缺氧和安慰剂之间的发病率相似;两名参与者经历了显著的氧气脱.
- 与安慰剂相比,FiO2 0.163的间歇性缺氧在参与者评级的症状中显示出适度的短期改善,但不是评估者评级的尺度;血清生物标志物没有显著差异.
结论:
- 缺氧调节是帕金森病患者的安全和可行的干预措施.
- 特殊的方案,如间歇性低氧在FiO2 0.163,可能提供暂时的症状缓解.
- 这些发现支持进一步调查低氧条件治疗PD治疗的长期安全性和有效性.
相关概念视频
Parkinson's Disease: Treatment
986
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
986
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K


